In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report), with a price target of $42.00.
Matthew Caufield has given his Buy rating due to a combination of factors including consistent support from key opinion leaders (KOLs) for lorundrostat’s approach to treating hypertension. The positive results from the Advance-HTN and Launch-HTN pivotal trials have reinforced confidence in lorundrostat’s potential. These trials demonstrated significant efficacy in treating uncontrolled and resistant hypertension, achieving acceptable thresholds for hyperkalemia levels, and showcasing the potential of lorundrostat within the aldosterone synthase inhibitor mechanism.
Furthermore, the unmet needs in the hypertension patient segments, particularly the large numbers of uncontrolled and resistant hypertension patients, highlight the demand for effective and safe treatment options. The Advance-HTN trial results, which showed a significant reduction in systolic blood pressure when lorundrostat was used as an add-on therapy, further support its potential in the market. These factors, combined with the positive reception of the trial data by specialists, underpin Caufield’s decision to maintain a Buy rating and increase the price target to $42 per share.
In another report released on March 31, Stifel Nicolaus also maintained a Buy rating on the stock with a $45.00 price target.